Refine by
Inflammation Chronic Articles & Analysis
19 news found
Lipids are essential to many body functions and serve as the building blocks for living cells. Alfa Chemistry has been an ISO 9001:2015 certified supplier of nearly all forms of lipids and fatty acids and continues to broaden its product lines by adding phospholipids, modified lipids, and functionalized lipids. These lipid molecules are recently added to the already well-established collection of ...
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that ...
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th. ANGANY’s primary focus is the development of therapeutic vaccines, leveraging the unique immunogenicity and safety profile of its ...
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical ...
One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with ...
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, - announced today that its Phase 2a clinical trial with its investigational drug product, DBI-001, in atopic dermatitis, has demonstrated decreases in the abundance in S. aureus, improvement in signs and symptoms of atopic dermatitis, and no safety or ...
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, ...
Nuritas, the world leader in artificial intelligence-based natural molecule discovery, has published an independent peer reviewed scientific paper in Foods Journal. The paper outlines the discovery of natural rice-based peptides clinically proven to impact inflammation and improve physical test results in an elderly population. Whilst these peptides are found within food, critically, their ...
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease. The trial, AKST4290-211 (TEAL), is funded in part by The Michael J. Fox Foundation for ...
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
SPECTRUM, the world’s largest single-device registry in ophthalmology, has completed enrollment. The announcement was made today by Ivantis Inc., a company dedicated to developing new and innovative solutions for glaucoma. SPECTRUM is a patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate primary open-angle ...
QXMédical acquired the world-wide exclusive rights to the bioresorbable embolic technology developed by researchers and physicians at the University of Minnesota to fill a clinical need for resorbable and drug-loadable microspheres and hydrogels. Embolics are used by interventional radiologists and oncologists to occlude vessels for a variety of clinical indications. Current market leaders ...
Researchers at INRA, INSERM, AP-HP, and UPMC have just discovered a new protein with anti-inflammatory properties, which has been named MAM (microbial anti-inflammatory molecule). It is secreted by the bacterium Faecalibacterium prausnitzii and helps fight intestinal inflammation. This discovery, recently published in the journal Gut, is a major advance in efforts to develop new means of treating ...
There is only a small chance of recovering from pancreatic cancer. This type of cancer has been linked to a number of risk factors, including smoking, but a new study suggests that pancreatic cancer may also be associated with exposure to certain herbicides. Other risk factors, in addition to smoking, that have been associated with a greater chance of developing pancreatic cancer include ...